Company Info
| Industry | Pharmaceuticals: Generic |
|---|---|
| Sector | Health Technology |
| Employees | 39,717 |
| CEO | Mr. Kåre Schultz |
| Address | 5 Basel Street , Petach Tikva, HM 4951033 |
|---|---|
| Phone | 972.3.926.7267 |
| Website | www.teva.co.il |
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| Teva Pharmaceutical Industries Ltd. | -15.08% | -19.34% |
| NovoCure Ltd. | -33.81% | -35.37% |
| Penumbra, Inc. | -10.47% | 10.03% |
| United Therapeutics Corp. | -11.77% | 43.14% |
| Bausch Health Cos., Inc. | -19.09% | 23.34% |
Statement Summary
as of 4:10 ET PM 12/02/2021| Total Assets (MRQ) | 47.9 B |
|---|---|
| Total Liabilities (MRQ) | 36.4 B |
| Shareholders’ Equity (MRQ) | 11.5 B |
| Total Revenue (Annual) | 3.9 B |
| Net Income (Annual) | 290.0 M |
Earnings And Estimates
as of 4:10 ET PM 12/02/2021
| Current Qtr EPS Estimate | 0.73 |
|---|---|
| Current FY EPS Estimate | 2.55 |
| Long Term EPS Growth Estimate | 3.15 |
| Next Expected Earnings Date | // |
TEVA vs S&P 500
as of 12/02/2021| Relative To S&P 500 |
TEVA | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:10 ET PM 12/02/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 09/2021 | 0.64 | 0.59 | -8.47% |
| 06/2021 | 0.59 | 0.59 | -0.40% |
| 03/2021 | 0.59 | 0.63 | +6.64% |
| 12/2020 | 0.63 | 0.68 | +8.23% |
| 09/2020 | 0.58 | 0.58 | -0.36% |
| 06/2020 | 0.53 | 0.55 | +4.62% |
| 03/2020 | 0.59 | 0.76 | +28.45% |
| 12/2019 | 0.61 | 0.62 | +2.28% |
Financial Strength
as of 4:10 ET PM 12/02/2021| Pre-Tax Margin | 9.87 |
|---|---|
| Net Margin | 0.00 |
| Operating Margin | 17.26 |
| Return On Equity | 7.23 |
| Return On Assets | 1.49 |
| Inventory Turnover (TTM) | 2.00 |
| Sales Growth (MRQ) | -3.22 |
Ratios
as of 4:10 PM ET 12/02/2021| Price/Earnings (TTM) | 12.21 |
|---|---|
| Price/Book (MRQ) | 0.85 |
| Price/Cash Flow (TTM) | 3.96 |
| Book Value (MRQ) | 9.49 |
| Quick Ratio (MRQ) | 0.68 |
| Current Ratio (MRQ) | 1.03 |
| Total Debt/Equity (MRQ) | 2.31 |
Short Interest
as of 4:10 PM ET 12/03/2021| % Short - 1.78% | |
| % Remaining Float - 98.22% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | 11/15/2021 | 10/29/2021 |
| Short Interest Shares | 19,590,266 | 19,244,071 |
| Short Interest Ratio | 1.7 | 1.7 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:10 ET PM 12/02/2021| Current Qtr (12/2021) |
Next Qtr (03/2022) |
|
|---|---|---|
| Consensus Estimate | $0.73 | $0.63 |
| # of Estimates | 14 | 6 |
| High Estimate | $0.81 | $0.66 |
| Low Estimate | $0.67 | $0.58 |
| Year Ago EPS | $0.14 | $0.07 |
| Year Over Year Growth Estimate | 430.29% | 794.94% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $2.55 | $2.67 |
| # of Estimates | 15 | 15 |
| High Estimate | $2.65 | $2.80 |
| Low Estimate | $2.48 | $2.56 |
| Year Ago EPS | $2.57 | $2.55 |
| Year Over Year Growth Estimate | -0.92% | 5.01% |
| Current Qtr (12/2021) |
Next Qtr (03/2022) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $0.73 | $0.63 | $2.55 | $2.67 |
| # of Estimates | 14 | 6 | 15 | 15 |
| High Estimate | $0.81 | $0.66 | $2.65 | $2.80 |
| Low Estimate | $0.67 | $0.58 | $2.48 | $2.56 |
| Year Ago EPS | $0.14 | $0.07 | $2.57 | $2.55 |
| Year Over Year Growth Estimate | 430.29% | 794.94% | -0.92% | 5.01% |
Insider Information Summary
as of 11/30/2021| % Insiders - 0.01% | |
| % Remaining Total Shares - 99.99% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 0.00 | 0.00 |
| Shares Bought | 0.00 | 0.00 |
| Shares Sold | 0.00 | 0.00 |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Learn to Trade Like a Pro
Master The Market with the Help of Our Financial Experts
LATEST NEWS
Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns
Oct 4, 2021 3:05 PM EDT
Latest News
5 Top Stock Gainers for Wednesday: Tilray, Boeing and Alphabet
Jul 28, 2021 11:52 AM EDT
Teva Stock Climbs After Earnings Match Estimates
Jul 28, 2021 11:44 AM EDT
Teva Halts Search for Partners to Develop COVID-19 Vaccine
Apr 28, 2021 2:47 PM EDT
Teva's Fourth-Quarter Adjusted Earnings Top Forecasts
Feb 10, 2021 8:41 AM EST
Teva 3rd-Quarter Adjusted Profit Meets Estimate; Revenue Lags
Nov 5, 2020 9:23 AM EST
Magnificent Seven: Cramer's 'Mad Money' Recap (Monday 10/19/20)
Oct 19, 2020 7:16 PM EDT
Johnson & Johnson Faces New York State Fraud Action Linked to Opioid Crisis
Sep 17, 2020 11:17 AM EDT
Teva Is Said to Face U.S. Charge in Price-Fixing Inquiry
Aug 25, 2020 3:20 PM EDT
Teva Sued by U.S. Government Over Alleged Copaxone Kickbacks
Aug 18, 2020 11:53 AM EDT
Berkshire Hathaway Expected to Earn $2.12 a Share
Aug 7, 2020 8:22 PM EDT
State Attorneys General Sue Generic Drugmakers for Inflating Prices
Jun 10, 2020 12:25 PM EDT
New Market: Cramer's 'Mad Money' Recap (Thursday 5/28/20)
May 28, 2020 6:53 PM EDT
Buffett Exits Phillips 66 and Travelers, Trims Goldman Sachs
May 15, 2020 7:37 PM EDT
Teva Soars as Generic Drugmaker Tops Earnings and Revenue Estimates
May 7, 2020 9:07 AM EDT
Coronavirus Latest Updates: A Timeline of Recent Events
Mar 30, 2020 10:42 AM EDT
Teva Donates 6 Million Tablets of Malaria Drug to Fight Coronavirus in U.S.
Mar 20, 2020 10:44 AM EDT
Warren Buffett’s Berkshire Hathaway Takes Stakes in Kroger, Biogen; Cuts Banks and Apple
Feb 14, 2020 7:58 PM EST
Teva Pharmaceutical Jumps After Earnings Meet Wall Street Estimates
Feb 12, 2020 8:09 AM EST
Bernie Sanders, Coronavirus, Cisco, CVS and Lyft - 5 Things You Must Know Wednesday
Feb 12, 2020 5:11 AM EST
Opioid Companies Face U.S. Criminal Inquiry Under Drug-Dealing Law: Report
Nov 26, 2019 1:59 PM EST
Teva, Generic Drugmakers Reportedly Aiming to Settle U.S. Antitrust Inquiry
Nov 25, 2019 11:06 AM EST
Teva Shares Higher After Drugmaker Proposes $23B Global Opioid Settlement
Oct 21, 2019 4:52 PM EDT
Stocks End Higher on Renewed Hope for U.S.-China Trade Pact, Earnings Optimism
Oct 21, 2019 4:16 PM EDT
McKesson, Teva and Others Settle Ohio Counties Opioid Suit
Oct 21, 2019 12:49 PM EDT
Recent Articles from TheStreet
Move Over, Marvel! Amazon Is Building Its Own Superhero Universe
Amazon Prime Video has ordered The Boys: Diabolical, a spin-off of its popular superhero drama
Cryptocurrency Price Check: 'Don't Fight the Fed'
The 'overall weakness across the financial markets should be considered when trading crypto into the foreseeable future,' one analyst says.
Hackers Siphon $196 Million of Crypto From BitMart
Thieves relieved BitMart of $196 million of cryptocurrency by purloining a private key that gave them access to two BitMart wallets.
Donald Trump Media SPAC Digital World Acquisition In SEC Probe Linked To October Merger
The so-called blank check company preparing to bring Donald Trump's Truth Social media company public is being investigated by the U.S. Securities and Exchange Commission.
EV Disruptor Rivian Lauded on Wall Street With Valuation Caution
Wedbush views the Rivian story as a game changer for the EV market. Other firms are more cautious, given its valuation.
Samsung Sued by Caltech Over Alleged Wi-Fi Patent Infringement
Caltech charges Samsung's various products infringe five of its data-transmission patents.
GCP Applied Technologies Agrees to Acquisition by French Co. Saint-Gobain
GCP Applied Technologies agrees to be acquired by French counterpart Saint-Gobain for $32 a share in a deal that values the company at about $2.3 billion.
Apple Stock Jumps As KeyBanc Opens Coverage With 'Overweight' Rating, $191 Price Target
KeyBanc analyst Brandon Nispel initiated coverage of Apple with an 'overweight' rating and a $191 price target, citing strength in the tech giant's expanding services division.
Tesla Stock Slides On Report of SEC Probe Into Whistleblower Complaints Linked To Solar Panel Risks
Reuters reported Monday that the SEC is looking into allegations from a former employee that it failed to properly communicate risks linked to fire risks in its solar panels.
Hertz Stock Rises as Analysts Initiate Coverage of Car-Rental Giant
Hertz shares are higher. Several analysts initiate coverage as the car-rental giant continues its climb out of bankruptcy proceedings.